New therapy shrinks tumors to treat lung cancer
The need for more effective lung cancer treatments is paramount, as the disease remains a leading cause of cancer deaths in the United States. New findings by a research team from the Stony Brook Cancer Center highlight a novel therapeutic shown to be highly effective in reducing non-small cell lung cancer (NSCLC) tumors and appearing to halt drug resistance in a laboratory model.
Lung cancer remains a leading cause of cancer deaths in the United States, making the need for more effective treatments critical. A research team from Stony Brook Cancer Center has developed a novel therapeutic called Gem-miR-129 that shows promise in combating drug resistance and shrinking tumors in non-small cell lung cancer (NSCLC) models.
Led by Jingfang Ju, Ph.D., this multitargeted, multimodal miRNA-129-based therapy combines a naturally occurring cancer-fighting molecule with a commonly used chemotherapy drug to simultaneously shut down three oncogenic driver proteins. In lab tests, Gem-miR-129 reduced tumor burden by over 95% and increased survival time in mice by several weeks.
This approach may provide a solution for NSCLC patients who develop resistance to standard treatments, such as gemcitabine and EGFR inhibitors, as it not only eliminates drug-resistant tumor cells but also enhances the activity of antitumor T cells. While the safety and efficacy of Gem-miR-129 in humans have not yet been tested, this promising development could pave the way for future clinical trials.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
